BACKGROUND: Par j 1 represents a major allergenic component of Parietaria judaica (Pj) pollen, since it is able to induce an immunoglobulin E (IgE) response in 95% of Pj-allergic patients. It belongs to the non-specific lipid transfer protein family, sharing with them a common three-dimensional structure. METHODS: Disulphide bond variants of the recombinant Par j 1 (rPar j 1) allergen were generated by site-directed mutagenesis, and the immunological activity of rPar j 1 and its conformational mutants was compared with the use of the skin prick test (SPT). The ability to bind IgE antibodies was evaluated by Western blot, ELISA and ELISA inhibition. T cell reactivity was measured by peripheral blood mononuclear cell proliferation assay. RESULTS: The disruption of Cys14-Cys29 and Cys30-Cys75 bridging (PjA mutant) caused the loss of the majority of specific IgE-binding activity. Additional disruption of the Cys4-Cys52 bridge (PjC mutant) and the latter Cys50-Cys91 bridge (PjD mutant) led to the abolition of IgE-binding activity. On the SPT, PjB (lacking the Cys4-Cys52 and Cys50-Cys91 bridges) was still capable of triggering a type I hypersensitive reaction in 9 out of 10 patients, and PjA in 3 out of 10 patients, while PjC and PjD did not show any SPT reactivity. All the mutants preserved their T cell reactivity. CONCLUSION: Recombinant hypoallergenic variants of the rPar j 1 allergen described herein may represent a useful tool for improved immunotherapy. Copyright 2001 S. Karger AG, Basel
BACKGROUND: Par j 1 represents a major allergenic component of Parietaria judaica (Pj) pollen, since it is able to induce an immunoglobulin E (IgE) response in 95% of Pj-allergicpatients. It belongs to the non-specific lipid transfer protein family, sharing with them a common three-dimensional structure. METHODS:Disulphide bond variants of the recombinant Par j 1 (rPar j 1) allergen were generated by site-directed mutagenesis, and the immunological activity of rPar j 1 and its conformational mutants was compared with the use of the skin prick test (SPT). The ability to bind IgE antibodies was evaluated by Western blot, ELISA and ELISA inhibition. T cell reactivity was measured by peripheral blood mononuclear cell proliferation assay. RESULTS: The disruption of Cys14-Cys29 and Cys30-Cys75 bridging (PjA mutant) caused the loss of the majority of specific IgE-binding activity. Additional disruption of the Cys4-Cys52 bridge (PjC mutant) and the latter Cys50-Cys91 bridge (PjD mutant) led to the abolition of IgE-binding activity. On the SPT, PjB (lacking the Cys4-Cys52 and Cys50-Cys91 bridges) was still capable of triggering a type I hypersensitive reaction in 9 out of 10 patients, and PjA in 3 out of 10 patients, while PjC and PjD did not show any SPT reactivity. All the mutants preserved their T cell reactivity. CONCLUSION: Recombinant hypoallergenic variants of the rPar j 1 allergen described herein may represent a useful tool for improved immunotherapy. Copyright 2001 S. Karger AG, Basel
Authors: Laurian Zuidmeer-Jongejan; Montserrat Fernandez-Rivas; Lars K Poulsen; Angela Neubauer; Juan Asturias; Lars Blom; Joyce Boye; Carsten Bindslev-Jensen; Michael Clausen; Rosa Ferrara; Paula Garosi; Hans Huber; Bettina M Jensen; Stef Koppelman; Marek L Kowalski; Anna Lewandowska-Polak; Birgit Linhart; Bernard Maillere; Adriano Mari; Alberto Martinez; Clare En Mills; Claudio Nicoletti; Dirk-Jan Opstelten; Nikos G Papadopoulos; Antonio Portoles; Neil Rigby; Enrico Scala; Heidi J Schnoor; Sigurveig T Sigurdardottir; George Stavroulakis; Frank Stolz; Ines Swoboda; Rudolf Valenta; Rob van den Hout; Serge A Versteeg; Marianne Witten; Ronald van Ree Journal: Clin Transl Allergy Date: 2012-03-09 Impact factor: 5.871
Authors: Stephanie Eichhorn; Angelika Hörschläger; Markus Steiner; Josef Laimer; Bettina M Jensen; Serge A Versteeg; Isabel Pablos; Peter Briza; Laurian Jongejan; Neil Rigby; Juan A Asturias; Antonio Portolés; Montserrat Fernandez-Rivas; Nikolaos G Papadopoulos; Adriano Mari; Lars K Poulsen; Peter Lackner; Ronald van Ree; Fatima Ferreira; Gabriele Gadermaier Journal: Mol Nutr Food Res Date: 2019-06-26 Impact factor: 5.914